MDV.AX - Stock quotes

Live Stock Quotes - Symbol Lookup

Ticker :	MDV.AX
Last Trade :	0.012
Last Trade At :	2/8/2012 11:15pm
Change :	0.000
Opened At :	0.012
Day Range :	0.012 - 0.011
Volume :	1545761
More Details:	http://finance.yahoo.com/q?s=MDV.AX

Data delayed by 15 minutes

Detailed Chart for MDV.AX and Technical Analysis

News Headlines for MDV.AX

IMPORTANT: Bing News RSS feed has moved!
table bgColorffffbb border1pxtdGo to thenbspa hrefhttpapi.bing.comrss.aspxSourceNewsampMarketen-USampVersion2.0 ampQueryMDV.AXnew RSS pageanbspand renew your subscription.tdtable

Prostate Cancer Drug: How to Find Clinical Trials of Promising Med
Prostate cancer got a kick in the pants Thursday when researchers presented a new promising drug that greatly improves survival rates in patients. The experimental drug named MDV3100 reduced the risk of death in prostate cancer patients by 37 ...

Kenwood Debuts Rovi Media Recognition Solution with iPhone Capability for Car Navigation Systems in Japan
The app KENWOOD Music Info. can already be downloaded for free from the iTunes App Store and the -737DT and -535DT navigation systems will be available for sale this month. About Rovi Corporation Rovi Corporation is focused on ...

Kenwood integrates Rovi Media Recognition solution with iPhone functionality
Feb 03 2012 Datamonitor via COMTEX -- Rovi Corporation has announced that Kenwood has integrated the Rovi Media Recognition solution with iPhone functionality into its new all-in-one AV integrated navigation systems in Japan the -737DT ...

Medivation/Astellas' MDV3100 Shines
Results showed a 4.8-month advantage in median overall survival compared to placebo 18.4 months versus 13.6 months. MDV3100 met its secondary endpoints as well compared to placebo. These included radiographic progression-free survival 8.3 ...

Provenge Is Probably More Effective Than We Think
There is a temptation to compare this 7.8 months median survival to the 3.8 months improvement in median overall survival seen with Zytiga and 4.8 months seen with 3100 in post chemotherapy prostate cancer patients. However the patient ...

Drug Extends Survival in Patients with Drug-Resistant Prostate Cancer
A new drug MDV3100 is improving the survival rate in men with advanced prostate cancer results of a large phase III clinical trial show. The drug is designed to block a type of cellular receptor that drives progression of prostate cancer. Based on the ...

How formal can eliminate IP integration uncertainty
Is the IP specification correct and complete We can now measure verification coverage and progress and we can ensure that weve completely implemented the specification. But how do we know that the specification is complete and correct to ...

Mutation drives viral sensors to initiate autoimmune disease
A new study uses a mouse model of a human autoimmune disease to reveal how abnormal regulation of the intracellular sensors that detect invading viruses can lead to autoimmune pathology. The research published online on January 26th in the journal ...

WB lobbied for disqualified firm: ACC
Dhaka Feb 2 bdnews24.comThe Anticorruption Commission on Thursday said the World Bank had repeatedly recommended a disqualified Chinese company for the Padma bridge project. The chief of the antigraft watchdog Golam Rahman at a media briefing ...

Phase 3 MDV3100 Data Released
Medivation Inc. and Astellas Pharma Inc. announced positive results on all efficacy endpoints from the Phase 3 AFFIRM trial of the investigational drug MDV3100 in men with prostate cancer previously treated with chemotherapy. MDV3100 ...

Live Stock Quotes